Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Beijing Konruns Pharmaceutical Co Ltd
603590Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including CX1026 for the treatment of lung, liver, kidney, colon, and skin T lymphocyte cancer; CX1003, which is in phase 1 trial for the treatment of solid tumors/preferably rare tumors; ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; KC-B173 for bleeding and prevention of bleeding during surgical or invasive procedures; and KC1036, which is in phase 2 clinical trial for the treatment of solid tumors. The company was founded in 2003 and is headquartered in Beijing, China. Address: No. 11, Xingsheng South Road, Beijing, China
Analytics
Zielpreis von Wall Street
322.02 CNYKGV
34.4658Dividendenrendite
–Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen 603590
Dividenden-Analyse 603590
Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
–Ausschüttungsquote 5-Jahres-Durchschnitt
36 %Verlauf der Dividende 603590
Bewertung der Aktie 603590
Finanzen 603590
Ergebnisse | 2019 | Dynamik |